Experienced in Pure Red Cell Aplasia

Dr. Ivana Gojo

Hematology Oncology | Hematology | Oncology

Johns Hopkins Medicine

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

Offers Telehealth

Experienced in Pure Red Cell Aplasia

Johns Hopkins Medicine

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ivana Gojo is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Gojo is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in MD

Hospital Affiliations

The Johns Hopkins Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Blue Cross Blue Shield

CareFirst

Cigna

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Johns Hopkins Healthcare

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE-MEDICAID PLAN

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 5 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287

Call: 410-955-8708

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Drug

Study Drug: Ruxolitinib

Study Phase: Phase 2

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: August 15, 2025

Intervention Type: Biological, Procedure

Study Drugs: Blinatumomab, Ipilimumab, Nivolumab

Study Phase: Phase 1

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: August 03, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Azacitidine, Pembrolizumab, Venetoclax

Study Phase: Phase 2

A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement

Enrollment Status: Terminated

Publish Date: June 18, 2025

Intervention Type: Drug

Study Drugs: Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Pinometostat

Study Phase: Phase 1/Phase 2

A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)